Navigation Links
Two studies published in the Lancet
Date:9/2/2007

Lexington, KY (Aug. 31, 2007) Two worldwide studies published in this week's edition of The Lancet observe the alarming growth rate of chronic obstructive pulmonary disease (COPD). The only U.S. site in the International Burden of Lung Disease (BOLD) Study was located in Eastern Kentucky, and was found to have some of the highest rates of COPD in the world. In fact, it had the second highest rate among women and fourth highest among men. Smoking is a primary risk factor for the disease, although it is heavily influenced by exposures to dusty working environments, air pollution, diet, and genetic factors.

Dr. David M. Mannino, a faculty member in the University of Kentucky College of Public Health and UK College of Medicine Division of Pulmonary, Critical Care and Sleep Medicine, is co-author of the studies. "Global burden of COPD: risk factors, prevalence, and future trends," concluded that higher levels and more advanced stages of COPD occur worldwide than previously thought. Furthermore, this burden will increase as the worlds population continues to age.

"International variation in the prevalence of chronic obstructive pulmonary disease (The BOLD Study): a population-based prevalence study," looked at risk factors, prevalence and future trends of COPD. The World Health Organization (WHO) estimates that in high-income countries, 73 percent of COPD mortality is related to smoking, with 40 percent related to smoking in nations with low and middle income populations. "Worldwide, tobacco smoke remains the most important cause of COPD," Mannino said. "Furthermore, smoking during pregnancy can negatively affect fetal lung growth and result in development of lung disease. We can not, however, ignore other factors important in COPD such as air pollution, diet, and occupational exposures. In addition, we see many patients in whom disease progresses years after they have stopped smoking, suggesting that we need new strategies to deal with this devastating disease."


'/>"/>
Contact: Ann Blackford
ann.blackford@uky.edu
859-323-6363
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Studies On Hearing Loss Discovers New Causes
2. Broccoli Found to Block Cancer Progression In Both Animal and Human Studies
3. Studies Report Mammograms Unsafe
4. Six Indians Win Australian Studies Fellowships
5. Cure For Autism Could Be Established Through Hamster Studies
6. Despite More Studies Researchers Are Still Confound With ADHD
7. Studies Show Brain becomes Less Specialized With Age
8. ISB To Establish Research Chair On Real Estate And Urban Studies
9. Studies Show Combination Drugs As A Poor Substitute For Anti-Coagulants In Stroke
10. Further Studies Needed To Completely Understand About Ventricular Fibrillation
11. Circumcision Studies to Continue Says Health Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class ... support to bring their novel lifesaving device for the everyday use of parents ... sensors, specially designed to read a child’s vital signs, and detect unusual symptoms ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... ... April 24, 2017 , ... According ... overdose deaths now claim the lives of 62 Americans each day.(1) Yet since ... drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: